The 8 most recent market catalysts affecting $HIT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 55
Health In Tech to Announce Third Quarter 2026 Financial Results on November 12, 2026
Health In Tech (HIT) has filed an 8-K to announce the date for its third-quarter 2026 financial results release and subsequent conference call. This is a standard corporate disclos…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 65
Health In Tech Rolls Out AI-Powered HitRix
Health In Tech (HIT) has launched HitRix, an AI-powered platform for self-funded medical stop-loss health insurance. This development is significant as it addresses a long-standing…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 65
HIT stock has given up its prior gain. Health In Tech shares were trading higher after the company announced the launch of HitRix. The company updated its FY26 revenue guidance, roughly inline with FY25.
The headline indicates a mixed reaction to corporate news for Health In Tech (HIT). The launch of a new product, HitRix, initially spurred positive sentiment, but the subsequent re…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Health In Tech shares are trading higher after the company announced the launch of HitRix. The company updated its FY26 revenue guidance, roughly inline with FY25.
The launch of HitRix is a significant corporate catalyst for Health In Tech, demonstrating innovation and potentially expanding their market share. The 'roughly inline' FY26 guidan…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Health In Tech Revises FY2026 Revenue Outlook To About $33M, Roughly In Line With 2025, Launches AI-Powered HitRix Insurance Platform
This headline presents a mixed signal for Health In Tech. The flat revenue outlook for FY2026, despite a new AI platform launch, suggests that the company anticipates a period of i…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
Maxim Group Maintains Buy on Health In Tech, Lowers Price Target to $3
This filing discloses that Maxim Group, through its analyst Allen Klee, has maintained a 'Buy' rating on Health In Tech (HIT) but has simultaneously lowered its price target from $…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
Health In Tech Affirms FY2026 Sales Guidance of $45.000M-$50.000M vs $46.813M Est
Health In Tech (HIT) filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping it unchanged at $45.000 million to $50.000 million. This is a neutral event as it simply co…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Health In Tech Q2 EPS $(0.04) Misses $(0.03) Estimate, Sales $8.057M Beat $7.547M Estimate
Health In Tech (HIT) reported a substantial Q2 earnings per share miss, coming in at $(0.04) compared to an estimated $(0.03), which is a 500% decline from the prior year. This ind…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.